Coherus Oncology (CHRS) Non-Current Debt (2016 - 2026)

Coherus Oncology has disclosed Non-Current Debt across 11 years of filings, most recently posting $37.2 million for Q2 2026.

• In Q2 2026, Non-Current Debt rose 1.03% year-over-year to $37.2 million; the TTM figure through Jun 2026 stood at $37.2 million (up 1.03% YoY), while the FY2025 annual figure was $37.1 million, up 0.96% from the prior year.
• Non-Current Debt came in at $37.2 million for Q2 2026 at Coherus Oncology, roughly flat from $37.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $246.5 million in Q4 2023 to a low of $36.5 million in Q2 2024.
• Average Non-Current Debt over 5 years is $126.2 million, with a median of $54.8 million recorded in 2024.
• Year-over-year, Non-Current Debt surged 323.39% in 2022 and tumbled 85.14% in 2024.
• Over 5 years, Non-Current Debt stood at $245.5 million in 2022, then increased by 0.41% to $246.5 million in 2023, then slumped by 85.11% to $36.7 million in 2024, then gained by 0.96% to $37.1 million in 2025, then grew by 0.53% to $37.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $37.2 million in Q2 2026, $37.1 million in Q1 2026, and $37.1 million in Q4 2025.